 | |
| Clinical data | |
|---|---|
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H11F3N4O2 |
| Molar mass | 336.274 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-58642 is a nonsteroidal antiandrogen (NSAA) derived from nilutamide with very high affinity and selectivity for the androgen receptor (AR), which made it among the most potent and efficacious antiandrogens known at the time of its discovery.[1] It was investigated for topical application for the treatment of androgenetic alopecia (male-pattern baldness), but development did not proceed past initial trial stages, and it is now only used for scientific research into the AR.[2][3]
See also[edit]
References[edit]
- ^ Battmann T, Branche C, Bouchoux F, Cerede E, Philibert D, Goubet F, Teutsch G, Gaillard-Kelly M (January 1998). "Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders". The Journal of Steroid Biochemistry and Molecular Biology. 64 (1–2): 103–11. doi:10.1016/S0960-0760(97)00151-9. PMID 9569015. S2CID 290926.
- ^ Sims NA, Clément-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, Baron R (May 2003). "A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice". The Journal of Clinical Investigation. 111 (9): 1319–27. doi:10.1172/JCI17246. PMC 154447. PMID 12727923.
- ^ Windahl SH, Galien R, Chiusaroli R, Clément-Lacroix P, Morvan F, Lepescheux L, Nique F, Horne WC, Resche-Rigon M, Baron R (September 2006). "Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor". The Journal of Clinical Investigation. 116 (9): 2500–9. doi:10.1172/JCI28809. PMC 1555662. PMID 16955145.